MedTrace Logo

Elite Sport and Development of Asthma

NCT00262587 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-05-16

No results posted yet for this study

Summary

International studies have shown that elite athletes have a high prevalence of respiratory symptoms and asthma as compared to normal subjects. It is unclear whether the increased prevalence of asthma in elite athletes reflects "traditional asthma" or whether it is a special form of "sports asthma". The treatment of elite athletes with asthma seems to vary widely, and only a few studies have focused on the treatment of elite athletes with asthma. Further knowledge of the pathogenesis of sports asthma would lead to a greater understanding and better treatment of the condition. This study will investigate the type of airway inflammation in elite athletes and examine the effect of treatment with inhaled steroids in combination with long-acting beta-agonists versus placebo in the same group.

Conditions

Interventions

DRUG

Seretide

Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)

DRUG

Placebo

Inhaled sugar powder in a placebo inhaler

Sponsors & Collaborators

  • Imperial College London

    collaborator OTHER

  • Anti Doping Danmark

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • The Research Foundation of Bispebjerg Hospital

    collaborator UNKNOWN

  • Ragnhild Ibsens Legat For Medicinsk Forskning

    collaborator OTHER

  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Thomas Lund, MD · Respiratory and Allergy Research Unit, Department of Respiratory Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00262587 on ClinicalTrials.gov